臨床神経学

第48回日本神経学会総会

<シンポジウム2-1>神経伝達機能イメージング:Cutting Edge
認知症および錐体外路性疾患における脳内アセチルコリンエステラーゼ活性のイメージング

篠遠 仁1)2)

1)旭神経内科リハビリテーション病院〔〒270-0022 千葉県松戸市栗ヶ沢789-10〕
2)放射線医学総合研究所分子イメージング研究センター

Carbon-11 labeled N-methylpiperidin-4-yl acetate ([11C]MP4A) and carbon-11 labeled N-methylpiperidin-4-yl propionate ([11C]MP4P) are acetylcholine analogues and have been successfully used for measurement of brain acetylcholinesterase (AChE) activity in vivo in humans. In Alzheimer's disease (AD), there is a significant loss of AChE activity in the cerebral cortex in association with mental decline. The reduction of AChE activity in the cerebral cortex is more remarkable in early-onset AD than late-onset AD. There is mild but significant reduction of AChE activity in the cerebral cortex, even in the early stage of Parkinson's disease (PD) without dementia. There is remarkable reduction of AChE activity in the entire cerebral cortex in both PD with dementia and dementia with Lewy bodies (DLB). In two patients with frontotemporal dementia with parkinsonism linked to chromosome 17, there was prominent reduction of AChE activity in the cerebral cortex and thalamus. In 12 patients with progressive supranuclear palsy, there was profound reduction of AChE activity in the thalamus but not in the cerebral cortex. In corticobasal degeneration, there is symmetrical loss of AChE activity in the sensori-motor cortex.

(臨床神経, 47:822−825, 2007)
key words:アセチルコリン, アルツハイマー病, パーキンソン病, レビー小体型認知症, ポジトロン断層撮影法

(受付日:2007年5月16日)